DK0776895T3 - Proteinkinase C inhibitor - Google Patents

Proteinkinase C inhibitor

Info

Publication number
DK0776895T3
DK0776895T3 DK96308318T DK96308318T DK0776895T3 DK 0776895 T3 DK0776895 T3 DK 0776895T3 DK 96308318 T DK96308318 T DK 96308318T DK 96308318 T DK96308318 T DK 96308318T DK 0776895 T3 DK0776895 T3 DK 0776895T3
Authority
DK
Denmark
Prior art keywords
inhibitor
protein kinase
kinase
protein
Prior art date
Application number
DK96308318T
Other languages
English (en)
Inventor
Michael Robert Jirousek
Margaret Mary Faul
Gary Lowell Engel
Nagy Alphonse Farid
Lori Ann Richardson
Leonard Larry Winneroski Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0776895T3 publication Critical patent/DK0776895T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
DK96308318T 1995-11-20 1996-11-18 Proteinkinase C inhibitor DK0776895T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US697095P 1995-11-20 1995-11-20

Publications (1)

Publication Number Publication Date
DK0776895T3 true DK0776895T3 (da) 1999-06-23

Family

ID=21723527

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96308318T DK0776895T3 (da) 1995-11-20 1996-11-18 Proteinkinase C inhibitor

Country Status (34)

Country Link
US (3) US5710145A (da)
EP (1) EP0776895B1 (da)
JP (1) JP3348859B2 (da)
KR (1) KR100304210B1 (da)
CN (1) CN1093759C (da)
AR (2) AR004717A1 (da)
AT (1) ATE172199T1 (da)
AU (1) AU711125B2 (da)
BR (1) BR9611724A (da)
CA (1) CA2237221C (da)
CO (1) CO4750823A1 (da)
CY (1) CY2103B1 (da)
CZ (1) CZ297524B6 (da)
DE (1) DE69600784T2 (da)
DK (1) DK0776895T3 (da)
EA (1) EA000967B1 (da)
EG (1) EG23871A (da)
ES (1) ES2122764T3 (da)
HU (1) HU226821B1 (da)
IL (1) IL124417A (da)
MX (1) MX9803792A (da)
MY (1) MY118068A (da)
NO (1) NO310196B1 (da)
NZ (1) NZ323571A (da)
PE (1) PE22798A1 (da)
PL (1) PL184715B1 (da)
RO (1) RO120074B1 (da)
SI (1) SI0776895T1 (da)
TR (1) TR199800759T2 (da)
TW (1) TW403754B (da)
UA (1) UA61897C2 (da)
WO (1) WO1997018809A1 (da)
YU (1) YU49315B (da)
ZA (1) ZA969646B (da)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
ATE423089T1 (de) * 1998-01-30 2009-03-15 Daiso Co Ltd Verfahren zur herstellung von butantriol- derivaten
US6225301B1 (en) * 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) * 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
ATE251624T1 (de) * 1998-03-13 2003-10-15 Univ British Columbia Granulatimide-derivate zur behandlung von krebs
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
EP1297168A2 (en) * 2000-07-03 2003-04-02 Gala Design, Inc. Expression vectors
US6300106B1 (en) * 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
US7384738B2 (en) * 2002-03-28 2008-06-10 Bremel Robert D Retrovirus-based genomic screening
US20040038304A1 (en) * 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
EP1501511A4 (en) * 2002-05-06 2006-06-07 Univ Washington METHODS OF TREATING GLAUCOMA AND OTHER CONDITIONS INDUCED BY EXPRESSION OF NOS-2 BY INHIBITING THE EGFR PATHWAY
DE10244453A1 (de) * 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7232842B2 (en) * 2003-01-10 2007-06-19 Board Of Trustees Of The Leland Stanford Junior University Kinase inhibitors and associated pharmaceutical compositions and methods of use
JP4928261B2 (ja) 2003-06-18 2012-05-09 トランザイム・ファーマ・インコーポレイテッド モチリン受容体の大環状拮抗薬
US20050152942A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20050221429A1 (en) * 2004-01-16 2005-10-06 Cardinal Health Pts, Llc Host cells containing multiple integrating vectors comprising an amplifiable marker
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
US20090111786A1 (en) * 2004-12-03 2009-04-30 Glass Christopher K Compounds that Prevent Macrophage Apoptosis and Uses Thereof
US20070281988A1 (en) * 2004-12-20 2007-12-06 Cameron Norman E Combination Therapy for Vascular Complications Associated with Hyperglycemia
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP1877424A4 (en) * 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
US8508369B2 (en) 2006-09-01 2013-08-13 Intermec Ip Corp. RFID tag system with block coding, such as space-time block coding
PE20091522A1 (es) * 2007-12-21 2009-10-29 Novartis Ag Composicion farmaceutica solida que contiene 3-(1.h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4-il]-quinazolin-4-il]-pirrol-2,5-diona
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
AU2011234644B2 (en) 2010-03-30 2014-07-17 Novartis Ag PKC inhibitors for the treatment of B-cell lymphoma having chronic active B-cell-receptor signalling
TR201806682T4 (tr) 2012-11-29 2018-06-21 Novartis Ag Farmasötik kombinasyonlar.
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US20180185259A1 (en) 2016-12-19 2018-07-05 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
CA3071114A1 (en) 2017-07-28 2019-01-31 Applied Therapeutics Inc. Compositions and methods for treating galactosemia
CA3176768A1 (en) 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK278989B6 (sk) * 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
WO1994007895A1 (en) * 1992-09-25 1994-04-14 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
PT657458E (pt) * 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
PE22798A1 (es) 1998-05-11
ATE172199T1 (de) 1998-10-15
BR9611724A (pt) 1999-06-01
HUP9903377A2 (hu) 2000-02-28
DE69600784T2 (de) 1999-04-08
CY2103B1 (en) 2002-04-05
KR100304210B1 (ko) 2001-11-05
US6015807A (en) 2000-01-18
ZA969646B (en) 1998-05-18
KR19990067596A (ko) 1999-08-25
YU60996A (sh) 1999-03-04
CO4750823A1 (es) 1999-03-31
WO1997018809A1 (en) 1997-05-29
RO120074B1 (ro) 2005-08-30
PL184715B1 (pl) 2002-12-31
UA61897C2 (en) 2003-12-15
PL326754A1 (en) 1998-10-26
MX9803792A (es) 1998-09-30
CN1202825A (zh) 1998-12-23
CA2237221C (en) 2003-03-25
HUP9903377A3 (en) 2000-04-28
US5710145A (en) 1998-01-20
HU226821B1 (en) 2009-11-30
JPH11500149A (ja) 1999-01-06
CZ297524B6 (cs) 2007-01-03
US6117861A (en) 2000-09-12
SI0776895T1 (en) 1999-04-30
EP0776895A1 (en) 1997-06-04
TR199800759T2 (xx) 2001-01-22
MY118068A (en) 2004-08-30
YU49315B (sh) 2005-06-10
NO982182L (no) 1998-05-13
CZ150298A3 (cs) 1998-12-16
NO310196B1 (no) 2001-06-05
EP0776895B1 (en) 1998-10-14
NZ323571A (en) 1998-12-23
TW403754B (en) 2000-09-01
ES2122764T3 (es) 1998-12-16
EA199800374A1 (ru) 1998-10-29
AU1054897A (en) 1997-06-11
AR004717A1 (es) 1999-03-10
IL124417A0 (en) 1998-12-06
JP3348859B2 (ja) 2002-11-20
AR004336A1 (es) 1998-11-04
EG23871A (en) 2007-11-27
AU711125B2 (en) 1999-10-07
NO982182D0 (no) 1998-05-13
EA000967B1 (ru) 2000-08-28
DE69600784D1 (de) 1998-11-19
CN1093759C (zh) 2002-11-06
CA2237221A1 (en) 1997-05-29
IL124417A (en) 2002-11-10

Similar Documents

Publication Publication Date Title
DK0776895T3 (da) Proteinkinase C inhibitor
NO974453L (no) Proteinkinase C-hemmere
DE69435267D1 (de) Proteinkinase C Inhibitoren
DE69627179D1 (de) Substituierte 2-anilino-pyrimidines verwendbar als protein kinase inhibitoren
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
NO992336D0 (no) Raf-kinase-inhibitorer
DE69323185D1 (de) Proteinkinase c-inhibitor
PT858464E (pt) Inibidores de trombina
DE69622983T2 (de) Chip-spule
DE69618742T2 (de) Schaltungsanordnung
PT863916E (pt) Tripeptidos de polifluoroalquil triptofano inibidores de trombina
DE69734817D1 (de) Neuartige amp-aktivierte proteinkinase
DE69619622T2 (de) Schaltungsanordnung
BR9610514A (pt) Inibidores cicloantihelmínticos
FI1943U1 (fi) Bomsystem till skogmaskin
KR960033453U (ko) 건강음료 보약탕기
ITMI930345A0 (it) N-acil-peptidi inibitori delle protein-chinasi
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
DE29519277U1 (de) Speicherschaltungsanordnung
FI950022A0 (fi) Eosinofiiliset kemotaksiainhibiittorit
KR970048502U (ko) 칩
ES1032844Y (es) Estanteria flotante
UA25624A (uk) Магhітооптичhа зчитувальhа головка
FI2196U1 (fi) Snoestyrningsblad till snoeslunga
FI2002U1 (fi) Haollare till spoestaell